Welcome to our dedicated page for Atrion news (Ticker: ATRI), a resource for investors and traders seeking the latest updates and insights on Atrion stock.
Atrion Corp (Symbol: ATRI) is a specialized medical device company headquartered at 527 Plymouth Rd, Plymouth, Pennsylvania, United States. The company is renowned for its development and manufacturing of high-quality products used primarily in medical applications.
Atrion's portfolio includes fluid-delivery products which generate the largest portion of its revenue. These products, such as specialized valves, are designed to hold and release controlled amounts of fluids or gases, making them essential in areas such as anesthesia and oncology.
Another significant segment of Atrion's business is its cardiovascular product line. The flagship product in this category is the MPS2 Myocardial Protection System. This advanced system is crucial during open-heart surgeries as it manages the delivery of fluids and medications, drug mixing, and the control of temperature and pressure. In addition to the MPS2, Atrion offers cardiac-surgery vacuum relief valves, inflation devices, and other essential tools used in cardiac procedures.
The company's ophthalmic products include medical devices aimed at disinfecting contact lenses, ensuring eye care professionals and patients have access to effective and reliable solutions.
Atrion Corp primarily generates its revenue within the United States, making it a significant player in the domestic medical devices industry. The company is committed to maintaining high standards of operational excellence and product quality.
In terms of financial performance, 2023 proved challenging for Atrion. The company reported revenues of $169.3 million, a decrease of $14.2 million from the previous year. Net income also saw a decline, reaching $19.4 million, down from $35 million. Diluted earnings per share were $11.02, compared to $19.56 the prior year. According to Mr. Battat, the CEO, the drop in performance was primarily due to global supply chain issues affecting the availability of electronic components crucial for their MPS 3 cardiac surgery consoles. Despite these challenges, Atrion decided to retain its skilled workforce to be better positioned for a rebound in demand in 2024 and beyond.
For more information and the latest updates, investors and stakeholders can contact Cindy Ferguson, Vice President and Chief Financial Officer, at (972) 390-9800.
Atrion Corporation (NASDAQ: ATRI) reported strong fourth-quarter and full-year 2022 results. Q4 revenues reached $42.9 million, a 6% increase from $40.3 million in Q4 2021, with operating income rising 12% to $8.8 million. Full-year revenues grew 11% to $183.5 million, while net income increased to $35 million from $33.1 million. The diluted earnings per share for 2022 rose to $19.56 from $18.18. The company noted a slight decline in gross profit margin due to rising costs. Despite challenges, Atrion remains debt-free and is investing in future growth, including a $41 million ERP system and facility expansions.
Atrion Corporation (NASDAQ: ATRI) declared a quarterly dividend of $2.15 per share on February 27, 2023. This dividend is set to be paid on March 31, 2023, to stockholders who are on record by the close of business on March 15, 2023. Atrion focuses on developing and manufacturing products for medical applications, enhancing its commitment to shareholder returns through consistent dividend payments. For further information, visit Atrion's website.
Atrion Corporation (NASDAQ: ATRI) has declared a quarterly dividend of $2.15 per share on its outstanding shares of Common Stock. The dividend is set to be paid on December 15, 2022, to stockholders of record as of the close of business on December 1, 2022. Atrion Corporation focuses on developing and manufacturing products for medical applications.
Atrion Corporation (NASDAQ: ATRI) reported third-quarter 2022 revenues of $44.6 million, up from $42.9 million in 2021, marking a 4% increase. Operating income rose to $9.6 million, while net income increased to $8.8 million, representing 7% and 8% growth respectively. Diluted earnings per share were $4.94, compared to $4.58 a year earlier. Despite challenges from Hurricane Ian, the company faced only delayed shipments costing $1.7 million. The CEO noted international recession concerns could shift customer orders to 2023, although gains are still expected.
Atrion Corporation (NASDAQ: ATRI) announced a succession plan appointing Cindy Ferguson as Vice President and Chief Financial Officer, effective March 4, 2023. This move follows the retirement of Jeffery Strickland, who has served in the role since 1997. Ferguson joined Atrion in June 2021 as the Company’s Controller, bringing 17 years of experience from Texas Instruments. The transition is designed to ensure stability and continuity in leadership. The Company specializes in developing medical products, with a focus on advancing future successes.
Atrion Corporation (Nasdaq ATRI) has announced an increase in its quarterly cash dividend from $1.95 to $2.15 per share. This increase reflects a commitment to enhance shareholder value. The dividend is payable on September 30, 2022, to stockholders of record by the close of business on September 15, 2022. Atrion specializes in developing and manufacturing products for medical applications.
FAQ
What is the current stock price of Atrion (ATRI)?
What is the market cap of Atrion (ATRI)?
What does Atrion Corp specialize in?
Where is Atrion Corp located?
What are Atrion's main product lines?
How did Atrion perform financially in 2023?
Who can I contact for more information about Atrion Corp?
What impacted Atrion's financial performance in 2023?
What is the MPS2 Myocardial Protection System?
Where does Atrion generate most of its revenue?
What kind of ophthalmic products does Atrion offer?
Why did Atrion retain its workforce despite financial challenges?
